Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 316 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. The company has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Follow-Up Questions
Who is the CEO of Xenon Pharmaceuticals Inc?
Mr. Ian Mortimer is the President of Xenon Pharmaceuticals Inc, joining the firm since 2013.
What is the price performance of XENE stock?
The current price of XENE is $39.52, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Xenon Pharmaceuticals Inc?
Xenon Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Xenon Pharmaceuticals Inc market cap?
Xenon Pharmaceuticals Inc's current market cap is $3.0B
Is Xenon Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Xenon Pharmaceuticals Inc, including 10 strong buy, 14 buy, 1 hold, 0 sell, and 10 strong sell
